These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11673723)

  • 1. Is attempting suicide an adverse effect of oxybutynin in a child with enuresis nocturna?
    Coskun S; Yüksel H; Onag A
    Pediatr Emerg Care; 2001 Oct; 17(5):398. PubMed ID: 11673723
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy of imipramine with oxybutynin in children with enuresis nocturna.
    Tahmaz L; Kibar Y; Yildirim I; Ceylan S; Dayanç M
    Urol Int; 2000; 65(3):135-9. PubMed ID: 11054030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient bilateral blindness and posterior reversible encephalopathy syndrome: a rare complication of enuresis treatment.
    Branson JA; Dale RC
    J Paediatr Child Health; 2008 Jun; 44(6):380-2. PubMed ID: 18476934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of oxybutynin hydrochloride in the treatment of enuresis nocturna--a clinical and urodynamic study.
    Koşar A; Arikan N; Dinçel C
    Scand J Urol Nephrol; 1999 Apr; 33(2):115-8. PubMed ID: 10360452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New adverse effect of oxybutynin: "night terror".
    Valsecia ME; Malgor LA; Espíndola JH; Carauni DH
    Ann Pharmacother; 1998 Apr; 32(4):506. PubMed ID: 9562151
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of oxybutynin, pseudoephedrine and indomethacin in the treatment of primary nocturnal enuresis.
    Varan B; Saatçi U; Ozen S; Bakkaloğlu A; Beşbaş N
    Turk J Pediatr; 1996; 38(2):155-9. PubMed ID: 8701478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxybutynin, desmopressin and enuresis.
    Nevéus T
    J Urol; 2001 Dec; 166(6):2459-62. PubMed ID: 11696812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of tolterodine in children after oxybutynin failure.
    Bolduc S; Upadhyay J; Payton J; Bägli DJ; McLorie GA; Khoury AE; Farhat W
    BJU Int; 2003 Mar; 91(4):398-401. PubMed ID: 12603422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of driptan (oxybutinin) in patients with urgent forms of urination disorders].
    Loran OB; Pushkar' DIu; Tevlin KP
    Urol Nefrol (Mosk); 1998; (6):24-6. PubMed ID: 10051823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxybutynin does not affect cyclosporin blood levels.
    Springate JE
    Ther Drug Monit; 2001 Apr; 23(2):155-6. PubMed ID: 11294516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxybutynin-associated esotropia.
    Wong EY; Harding A; Kowal L
    J AAPOS; 2007 Dec; 11(6):624-5. PubMed ID: 18086433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxybutynin efficacy in the treatment of primary enuresis.
    Lovering JS; Tallett SE; McKendry JB
    Pediatrics; 1988 Jul; 82(1):104-6. PubMed ID: 3288951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of oxybutynin treatment on cognition in children with diurnal incontinence.
    Sommer BR; O'Hara R; Askari N; Kraemer HC; Kennedy WA
    J Urol; 2005 Jun; 173(6):2125-7. PubMed ID: 15879864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute-angle closure glaucoma as a side-effect of oxybutynin.
    Sung VC; Corridan PG
    Br J Urol; 1998 Apr; 81(4):634-5. PubMed ID: 9598644
    [No Abstract]   [Full Text] [Related]  

  • 15. Anticholinergics do not improve cure rate of alarm treatment of monosymptomatic nocturnal enuresis.
    Yucel S; Kol A; Guntekin E; Baykara M
    Urology; 2011 Mar; 77(3):721-4. PubMed ID: 21215431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exaggerated neurological side-effects of oral and intravesical oxybutynin in a patient with multiple sclerosis.
    Vaidyanathan S; Krishnan KR; Soni BM; Fraser MH
    Spinal Cord; 1997 Mar; 35(3):190-1. PubMed ID: 9076875
    [No Abstract]   [Full Text] [Related]  

  • 17. Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice.
    Movig KL; Egberts AC; Lenderink AW; Leufkens HG
    J Am Geriatr Soc; 2001 Feb; 49(2):234-5. PubMed ID: 11207885
    [No Abstract]   [Full Text] [Related]  

  • 18. [Neuropsychiatric adverse effects attributed to use of oxybutynin].
    t'Veld BA; Kwee-Zuiderwijk WJ; van Puijenbroek EP; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Mar; 142(11):590-2. PubMed ID: 9623118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal oxybutynin (oxytrol) for urinary incontinence.
    Dull P
    Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of systematic treatment based on overnight simultaneous monitoring of electroencephalography and cystometry.
    Kawauchi A; Imada N; Tanaka Y; Yamao Y; Watanabe H
    Eur Urol; 1998; 33 Suppl 3():58-61. PubMed ID: 9599741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.